Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05054751

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial of GB491 Combined With Fulvestrant in Subjects With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed on Prior Endocrine Therapy

Clinical Trial Summary

GB491-004 is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of GB491 in combination with fulvestrant in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05054751
Study type Interventional
Source Genor Biopharma Co., Ltd.
Contact Shawn YU, MD
Phone 18600332657
Email shawn.yu@genorbio.com
Status Recruiting
Phase Phase 3
Start date September 10, 2021
Completion date January 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05860465 - Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer Phase 2/Phase 3
Active, not recruiting NCT03781063 - Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Completed NCT03027245 - Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
Not yet recruiting NCT05172518 - Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer Phase 3
Recruiting NCT05430399 - Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer Phase 3
Terminated NCT00634088 - Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Phase 1
Not yet recruiting NCT05403333 - Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05296798 - A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) Phase 3
Completed NCT03437083 - A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
Recruiting NCT05744687 - Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer Phase 2/Phase 3
Active, not recruiting NCT06439771 - A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC Phase 2
Withdrawn NCT05212701 - To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer Phase 2